Comparison of the 2007 and 2013 ASCO/CAP evaluation systems for HER2 amplification in breast cancer - ScienceDirect
Pathologist's Corner – Dr. Hon on Breast Cancer Tissue Handling and Updates for Her-2 Testing
Frontiers | HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry - Modern Pathology
![PDF] Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/22a3980f48cd672241df3eaefc79b28510b3576b/10-Figure2-1.png "PDF] Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. | Semantic Scholar")
PDF] Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. | Semantic Scholar
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer - eBioMedicine
![PDF] American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/32ece30ca42786761f6116717941ca1d4449b4bc/8-Figure1-1.png "PDF] American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. | Semantic Scholar")
PDF] American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. | Semantic Scholar
Updated (2018) ASCO/CAP Guidelines for HER2 Testing in Breast Cancer - Insights
Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy | PLOS ONE
Interobserver Variation in the Assessment of Immunohistochemistry Expression Levels in HER2-Negative Breast Cancer: Can We Improve the Identification of Low Levels of HER2 Expression by Adjusting the Criteria? An International Interobserver Study -
CAP and ASCO Press Release - College of American Pathologists
![PDF] THE BOTTOM LINE Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer : American Society of Clinical Oncology / College of American Pathologists Clinical Practice Guideline Focused Update Guideline Questions | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/747f72db6685fa520b07391fb016bac6754d7633/9-Figure4-1.png "PDF] THE BOTTOM LINE Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer : American Society of Clinical Oncology / College of American Pathologists Clinical Practice Guideline Focused Update Guideline Questions | Semantic Scholar")
PDF] THE BOTTOM LINE Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer : American Society of Clinical Oncology / College of American Pathologists Clinical Practice Guideline Focused Update Guideline Questions | Semantic Scholar
CAP Quantitative Image Analysis of HER2 Immunohistochemistry for Breast Cancer
Frontiers | HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
Evolution of HER2-low expression from primary to recurrent breast cancer | npj Breast Cancer
Schematic diagram of the ''Algorithm for evaluation of human epidermal... | Download Scientific Diagram
Slide Title
Q&A column, 4/17 - CAP TODAY
CAP and ASCO Press Release - College of American Pathologists
PDF) American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
![PDF] THE BOTTOM LINE Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer : American Society of Clinical Oncology / College of American Pathologists Clinical Practice Guideline Focused Update Guideline Questions | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/747f72db6685fa520b07391fb016bac6754d7633/7-Figure1-1.png "PDF] THE BOTTOM LINE Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer : American Society of Clinical Oncology / College of American Pathologists Clinical Practice Guideline Focused Update Guideline Questions | Semantic Scholar")
PDF] THE BOTTOM LINE Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer : American Society of Clinical Oncology / College of American Pathologists Clinical Practice Guideline Focused Update Guideline Questions | Semantic Scholar
Effect of the 2013 ASCO-CAP HER2 Testing Guideline on the Management of IHC/ HER2 2+ Invasive Breast Cancer | Anticancer Research
Assessment of HER2 status in Gastroesophageal Adenocarcinoma (GEA)
Frontiers | Breast Cancer With a HER2 IHC2+ and FISH HER2/CEP17 Ratio ≥2.0 and an Average HER2 Gene Copy Number <4.0 per Tumor Cell: HER2 mRNA Overexpression Is a Rare Event
